Association between low-normal thyroid function and advanced liver fibrosis in metabolic dysfunction-associated fatty liver disease patients: a retrospective cohort study
- PMID: 38264763
- PMCID: PMC10805339
- DOI: 10.1093/gastro/goad076
Association between low-normal thyroid function and advanced liver fibrosis in metabolic dysfunction-associated fatty liver disease patients: a retrospective cohort study
Abstract
Background: Recent studies have found that thyroid function may be associated with the occurrence and development of advanced liver fibrosis in patients with metabolic dysfunction-associated fatty liver disease (MAFLD). However, the majority of such research has consisted of cross-sectional studies. This retrospective cohort study aimed to investigate the effect of low-normal thyroid function on advanced liver fibrosis in MAFLD patients over a 5-year period.
Methods: This retrospective cohort study enrolled 825 outpatients and inpatients with MAFLD who attended the Third Affiliated Hospital of Sun Yat-sen University (Guangzhou, China) between January 2011 and December 2018. Based on plasma thyroid hormone and thyroid-stimulating hormone levels, these patients were divided into two groups, namely a low-normal thyroid function group and a strict-normal thyroid function group. The fibrosis-4 score was used to assess advanced liver fibrosis. A chi-square test was conducted to compare the occurrence of advanced fibrosis between the groups.
Results: Among the 825 MAFLD patients, 117 and 708 were defined as having low-normal thyroid function and strict-normal thyroid function, respectively. Follow-up data were available for 767 patients (93.0%) during a 5-year period. Eight (7.5%) MAFLD patients with low-normal thyroid function and 26 (3.9%) with strict-normal thyroid function developed advanced liver fibrosis and the cumulative incidence was not significantly different (P = 0.163). Stratification analysis showed that the lean MAFLD patients (body mass index ≤ 23 kg/m2) with low-normal thyroid function had a higher risk of advanced liver fibrosis than the lean MAFLD patients with strict-normal thyroid function (P < 0.05).
Conclusion: Low-normal thyroid function is associated with advanced liver fibrosis among lean MAFLD patients.
Keywords: fatty liver; hepatic fibrosis; liver metabolism; thyroid function.
© The Author(s) 2024. Published by Oxford University Press and Sixth Affiliated Hospital of Sun Yat-sen University.
Conflict of interest statement
None declared.
Figures


Similar articles
-
Low thyroid function is associated with an increased risk of advanced fibrosis in patients with metabolic dysfunction-associated fatty liver disease.BMC Gastroenterol. 2023 Jan 5;23(1):3. doi: 10.1186/s12876-022-02612-3. BMC Gastroenterol. 2023. PMID: 36604612 Free PMC article.
-
Correlation between thyroid function, sensitivity to thyroid hormones and metabolic dysfunction-associated fatty liver disease in euthyroid subjects with newly diagnosed type 2 diabetes.Endocrine. 2023 May;80(2):366-379. doi: 10.1007/s12020-022-03279-2. Epub 2022 Dec 20. Endocrine. 2023. PMID: 36539681
-
The Ability of Lipoprotein (a) Level to Predict Early Carotid Atherosclerosis Is Impaired in Patients With Advanced Liver Fibrosis Related to Metabolic-Associated Fatty Liver Disease.Clin Transl Gastroenterol. 2022 Jul 1;13(7):e00504. doi: 10.14309/ctg.0000000000000504. Epub 2022 May 23. Clin Transl Gastroenterol. 2022. PMID: 35608296 Free PMC article.
-
Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) and Thyroid Function in Childhood Obesity: A Vicious Circle?Children (Basel). 2024 Feb 15;11(2):244. doi: 10.3390/children11020244. Children (Basel). 2024. PMID: 38397356 Free PMC article. Review.
-
MAFLD: an ideal framework for understanding disease phenotype in individuals of normal weight.Ther Adv Endocrinol Metab. 2024 May 27;15:20420188241252543. doi: 10.1177/20420188241252543. eCollection 2024. Ther Adv Endocrinol Metab. 2024. PMID: 38808010 Free PMC article. Review.
References
-
- Eslam M, Newsome PN, Sarin SK. et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol 2020;73:202–9. - PubMed
-
- Lim GEH, Tang A, Ng CH. et al. An observational data meta-analysis on the differences in prevalence and risk factors between MAFLD vs NAFLD. Clin Gastroenterol Hepatol 2023;21:619–29.e7. - PubMed
-
- Nguyen VH, Le MH, Cheung RC. et al. Differential clinical characteristics and mortality outcomes in persons with NAFLD and/or MAFLD. Clin Gastroenterol Hepatol 2021;19:2172–81.e6. - PubMed
-
- Wong VW, Wong GL, Woo J. et al. Impact of the new definition of metabolic associated fatty liver disease on the epidemiology of the disease. Clin Gastroenterol Hepatol 2021;19:2161–71.e5. - PubMed
LinkOut - more resources
Full Text Sources